Cost-effectiveness modelling for TB interventions

Gabriela B Gomez,
Associate Professor in economics of infectious diseases
An Introduction to tuberculosis modelling post-graduate course
TB Union Conference, October 2018, The Hague
Conflict of interest disclosure

- I have **no**, real or perceived, direct or indirect conflicts of interest that relate to this presentation.

- I have the following, real or perceived direct or indirect conflicts of interest that relate to this presentation:

<table>
<thead>
<tr>
<th>Affiliation / financial interest</th>
<th>Nature of conflict / commercial company name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tobacco-industry and tobacco corporate affiliate related conflict of interest</td>
<td></td>
</tr>
<tr>
<td>Grants/research support (to myself, my institution or department):</td>
<td></td>
</tr>
<tr>
<td>Honoraria or consultation fees:</td>
<td></td>
</tr>
<tr>
<td>Participation in a company sponsored bureau:</td>
<td></td>
</tr>
<tr>
<td>Stock shareholder:</td>
<td></td>
</tr>
<tr>
<td>Spouse/partner – conflict of interest (as above):</td>
<td></td>
</tr>
<tr>
<td>Other support or other potential conflict of interest:</td>
<td></td>
</tr>
</tbody>
</table>

This event is accredited for CME credits by EBAP and speakers are required to disclose their potential conflict of interest going back 3 years prior to this presentation. The intent of this disclosure is not to prevent a speaker with a conflict of interest (any significant financial relationship a speaker has with manufacturers or providers of any commercial products or services relevant to the talk) from making a presentation, but rather to provide listeners with information on which they can make their own judgment. It remains for audience members to determine whether the speaker’s interests or relationships may influence the presentation. Drug or device advertisement is strictly forbidden.
What is economic evaluation?

- The use of analytical methods to identify, measure, value and compare the costs and consequences of alternative interventions

Drummond et al. (2005)
Why is cost-effectiveness important?

- **Decision support tool**
- Resources are scarce, therefore we must make the best choices about how to use them:
  - evaluate whether our choices are **efficient**
    - *are they being used in a way that maximises good health?*
  - evaluate our choices in a transparent, systematic way
    - *demonstrate to others that resources are being used well*
Stages of an economic evaluation

• Defining the question
• Identifying, quantifying and valuing the resources required (costs)
• Identifying, quantifying and valuing the outcomes required (utilities)
• Analysing, presenting and interpreting the evidence for decision making
Stages of an economic evaluation

• Defining the question
• Identifying, quantifying and valuing the resources required (costs)
• Identifying, quantifying and valuing the outcomes required (utilities)
• Analysing, presenting and interpreting the evidence for decision making
What is the question?

• Strategic level
  • Should INH preventative therapy be given to those with HIV/AIDS?
  • Should we screen for TB outside symptomatic clinic attendees?

• Tactical level
  • Should three sputum examinations be carried out?
  • Should expanded case-finding be facility- or community-based?

• Defining comparisons
  • New services against do nothing
  • New technology against status quo technology
  • Multiple options/resource allocation (more realistic)
  • Doing less
What perspective should we take?

• When are patient/societal costs important?
• Change in resource use between intervention and alternatives?
• What do we mean by provider?
  • Health services/systems
  • Budgetary implications
Prioritising interventions - Q

Q: You are your country’s Minister of Finance. The TB programme sends you a request for additional funding for Xpert and EPI sends a proposal for adding a second dose of measles vaccination to the U5 immunisation schedule. Of course there isn’t enough money to do both but they both sound worthwhile…

What aspects of the problem would you consider to make a decision?
## Prioritising interventions - A

<table>
<thead>
<tr>
<th>Impact of health problems</th>
<th>Resources needed for intervention</th>
</tr>
</thead>
</table>
Impact of health problems
- Number of cases
- Number of deaths
- Disability, pain or suffering
- People with a risk factor
- Money spent on a health problem
- Lost income due to health problem

Resources needed for intervention
- Personnel
- Buildings/space
- Equipment
- Supplies & pharmaceuticals
- Transportation
- Training
- Social mobilisation and communication

Prioritising interventions - A
Stages of an economic evaluation

• Defining the question
• **Identifying, quantifying and valuing the resources required (costs)**
• Identifying, quantifying and valuing the outcomes required (utilities)
• Analysing, presenting and interpreting the evidence for decision making
Financial vs economic costs

• Financial costs
  • Price tag
• Economic costs
  • Opportunity costs
Classifying costs

**Direct**

**Recurrent/Variable**
- Staff / Personnel, Supplies, Utilities, Admin, Travel, Other operating cost

**Capital/Fixed**
- Buildings, Equipment, Vehicles, Furniture, Once-off training

**Indirect**

- Community wide loss of production
- Waiting time
- Pain
- Illness related absenteeism

**Patient**
- Medical (consultations, hospital, admission, drugs)
- Travel
Q: The following slide shows an image from a lab

What resource items in the picture should be added up and valued to calculate the cost per test?

And what resources are not in the picture but are still necessary to deliver the intervention?
Stages of an economic evaluation

• Defining the question
• Identifying, quantifying and valuing the resources required (costs)
• Identifying, quantifying and valuing the outcomes required (utilities)
• Analysing, presenting and interpreting the evidence for decision making
What is utility?

• Sense of wellbeing/satisfaction associated with health states
• Used to describe (and measure) preferences for health states
Measuring effects - Q

Q: Case-finding, early diagnosis and linkage to treatment can prevent morbidity and deaths from TB. The question is how do we measure and value the benefits of avoiding these negative outcomes.

How do you measure the impact of the death from TB of a mother of three, who was the only school teacher in the village?
Measuring effects - A

How do you measure the impact of the death from TB of a mother of three, who was the only school teacher in the village?

• A ‘case’ of TB mortality
• The number of years she has lost from premature death
• The value of her wages her family has lost
• The effect of the loss of her wages on her children’s schooling – school fees can no longer be afforded
• Pain and suffering to her husband and children
• Loss of the investment her parents made toward her education
• Loss to the school system which now has to hire and train a replacement
QALYs

Utility weights derived through direct elicitation or indirectly from general population surveys (e.g. EQ-5D) and then applied to different conditions

Example:
Treatment A extends life by 10 years in perfect health:
\[ \text{QALYs} = 10 \times 1 = 10 \]
Treatment B extends life by 10 years in a state with 0.5 utility
\[ \text{QALYs} = 10 \times 0.5 = 5 \]
Direct methods

• Person trade-off
  • *Extend by one year the lives of 200 people, or extend the lives of 1000 people with one year living confined to bed?*

• Standard gamble
  • *Would you rather live with TB, or undergo treatment that can restore health with a 20% risk of death?*

• Time trade-off
  • *20 years of living with a physical disability compared to 10 years of healthy life?*

• Visual analogue scale
  • *How well are you feeling today?*
## Indirect methods

The EQ-5D descriptive system should be scored as follows:

<table>
<thead>
<tr>
<th>Dimension</th>
<th>Description</th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mobility</td>
<td>I have no problems in walking about</td>
<td>☑️</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>I have some problems in walking about</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>I am confined to bed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Self-Care</td>
<td>I have no problems with self-care</td>
<td></td>
<td>☑️</td>
<td></td>
</tr>
<tr>
<td></td>
<td>I have some problems with self-care</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>I am unable to wash or dress myself</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Usual Activities</td>
<td>I have no problems with performing my usual activities</td>
<td>☑️</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>I have some problems with performing my usual activities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>I am unable to perform my usual activities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain/Discomfort</td>
<td>I have no pain or discomfort</td>
<td></td>
<td>☑️</td>
<td></td>
</tr>
<tr>
<td></td>
<td>I have moderate pain or discomfort</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>I have extreme pain or discomfort</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anxiety/Depression</td>
<td>I am not anxious or depressed</td>
<td></td>
<td>☑️</td>
<td></td>
</tr>
<tr>
<td></td>
<td>I am moderately anxious or depressed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>I am extremely anxious or depressed</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NB:** There should be only one response for each dimension.

This example identifies the state: 11232.
DALYs

- Sum of the years of life lost due to premature mortality (YLLs) and years of life lost due to time lived in health states less than ideal health/disability (YLDs)
- They are a measure of the health gap between actual health and a defined ideal for health achievement
- DALYs are a ‘bad’ and health interventions should aim to avoid them
100% of life
(no health problems)
Disease $d$ with weight $dw$ that last for $t$ years
Health state

YLD

DALYS = N*dw * t
YLL=0 so far

1 -dw

t years

Age (years)

0 5 10 15 20 25 30 35 40 45 50 55 60

1
Early death at 45 years

DALYS = N*dw * t
YLL=0 so far

YLD
Health state

Age (years)

0 5 10 15 20 25 30 35 40 45 50 55 60

QALYs

Early death at 45 years

DALYS = (I*dw*t) + (N* (61-45))

YLD

YLL

0 1 2 3 4 5 6

1-dw

Health state

1

QALYs

Early death at 45 years

DALYS = (I*dw*t) + (N* (61-45))

YLD

YLL

0 5 10 15 20 25 30 35 40 45 50 55 60

Age (years)
Stages of an economic evaluation

• Defining the question
• Identifying, quantifying and valuing the resources required (costs)
• Identifying, quantifying and valuing the outcomes required (utilities)
• Analysing, presenting and interpreting the evidence for decision making
Model choice

• Empirical / single study
  – Cost and effects measured as part of trial – all costs and effects fall on the participants of the trial within the time frame of the trial

• Extending time period
  – Use of cohort models to project long-term costs and effects

• Extending populations and time period
  – Use of transmission models

• Extending scope
  – Use of health systems models

• Combination
  – Complexity vs comprehensiveness
Cost-effectiveness ratios

• Average cost effectiveness ratio (ACER)

\[
\frac{\text{Total cost of intervention } A}{\text{Total impact of intervention } A} \quad \frac{\text{Total cost of intervention } B}{\text{Total impact of intervention } B}
\]

• Incremental cost effectiveness ratio (ICER)

\[
\frac{(\text{Total cost of intervention } A - \text{Total cost of intervention } B)}{(\text{Total impact of intervention } A - \text{Total impact of intervention } B)}
\]
Cost-effectiveness plane

- New treatment more expensive
- New treatment less effective
- New treatment more effective
- New treatment less expensive

NO

??

YES
Willingness-to-pay thresholds

Probability the intervention is cost-effective

Willingness to pay per DALY averted US$

- A: $2,000 per DALY
- B: $3,000 per DALY
Issues and alternatives to WTP

• Aspirational or reflective of budget constraint
• Elicited or observed

Alternatives
• Ranking
• Combinations under a budget constraint
• Scenarios / choice sets or optimisation

Other values
Summary

• Cost-effectiveness not formulaic
• Decisions, values, uncertainty
• Transparency is key
• Models can assist in improving clarity from complexity
• But lots of moving parts and data scarcity, so important to be clear about each decision and uncertainty